ICON公共 ICLR 深 滬
已收盤 12-19 16:00:00 美东时间
173.77
-4.930
-2.76%
華盛通- 最 高178.75
- 今 開177.94
- 成交量 141.19万股
- 最 低 172.79
- 昨 收 178.70
- 總市值 138.09亿
- 52周最高 228.285
- 市盈率 靜 18.23
- 換手率 0.00%
- 52周最低 125.10
- 委 比 33.33%
- 總股本 7946.43万
- 歷史最高 347.7225
- 量 比 1.71
- 振 幅 3.34%
- 歷史最低 15.03
- 每 手 1
- 風險率 22.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
Barclays Maintains Equal-Weight on Icon, Raises Price Target to $200
Barclays analyst Luke Sergott maintains Icon (NASDAQ:ICLR) with a Equal-Weight and raises the price target from $185 to $200.
12-16 05:00
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
BMO Capital Initiates Coverage On Icon with Market Perform Rating, Announces Price Target of $175
BMO Capital analyst Sean Dodge initiates coverage on Icon (NASDAQ:ICLR) with a Market Perform rating and announces Price Target of $175.
11-13 17:35
Netskope ticks up after receiving Buy rating from Baird
Netskope (NASDAQ:NTSK) edged up 3% during early market action Monday after Baird initiated coverage on the cybersecurity company with a Buy rating. The Santa Clara-based company recently launched its ...
10-27 22:45
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
6 Analysts Assess Icon: What You Need To Know
6 analysts have shared their evaluations of Icon (NASDAQ:ICLR) during the recen...
10-24 22:00
Barclays Maintains Equal-Weight on Icon, Lowers Price Target to $185
Barclays analyst Luke Sergott maintains Icon (NASDAQ:ICLR) with a Equal-Weight and lowers the price target from $190 to $185.
10-24 21:45
Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent
Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, whic...
10-24 19:19
